<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD02810000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P04818</UniProt_ID>
  <Seq_Length>313</Seq_Length>
  <Molecule_Weight>35716</Molecule_Weight>
  <KEGG_ID>hsa:7298</KEGG_ID>
  <Orthology_ID>K00560</Orthology_ID>
  <Function_Summary>Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.</Function_Summary>
  <Catalytic_Mechanism>5,10-methylenetetrahydrofolate + dUMP = dihydrofolate + dTMP.</Catalytic_Mechanism>
  <Pfam_ID>PF00303:Thymidylat_synt</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>14</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>TS</Alias>
      <Alias>Tsase</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a methyl group to an acceptor molecule.</Detail>
      <Keyword>Methyltransferase activity</Keyword>
      <Ontology_ID>GO:0008168</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: 5,10-methylenetetrahydrofolate + dUMP = 7,8-dihydrofolate + thymidylate.</Detail>
      <Keyword>Thymidylate synthase activity</Keyword>
      <Ontology_ID>GO:0004799</Ontology_ID>
    </Funtion>
  </Function_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>A series of molecular signals in which a cell uses a phosphatidylinositol-mediated signaling to convert a signal into a response. Phosphatidylinositols include phosphatidylinositol (PtdIns) and its phosphorylated derivatives.</Detail>
      <Keyword>Phosphatidylinositol-mediated signaling</Keyword>
      <Ontology_ID>GO:0048015</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving pyrimidine bases, 1,3-diazine, organic nitrogenous bases.</Detail>
      <Keyword>Pyrimidine base metabolic process</Keyword>
      <Ontology_ID>GO:0006206</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway.</Detail>
      <Keyword>DNA repair</Keyword>
      <Ontology_ID>GO:0006281</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular metabolic process in which a cell duplicates one or more molecules of DNA. DNA replication begins when specific sequences, known as origins of replication, are recognized and bound by initiation proteins, and ends when the original DNA molecule has been completely duplicated and the copies topologically separated. The unit of replication usually corresponds to the genome of the cell, an organelle, or a virus. The template for replication can either be an existing DNA molecule or RNA.</Detail>
      <Keyword>DNA replication</Keyword>
      <Ontology_ID>GO:0006260</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the formation of nucleotides, any nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the glycose moiety; may be mono-, di- or triphosphate; this definition includes cyclic-nucleotides (nucleoside cyclic phosphates).</Detail>
      <Keyword>Nucleotide biosynthetic process</Keyword>
      <Ontology_ID>GO:0009165</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that regulates transcription such that the target genes are transcribed as part of the G1/S phase of the mitotic cell cycle.</Detail>
      <Keyword>Regulation of transcription involved in G1/S phase of mitotic cell cycle</Keyword>
      <Ontology_ID>GO:0000083</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the formation of one of a family of organic molecules consisting of a pyrimidine base covalently bonded to a sugar ribose (a ribonucleoside) or deoxyribose (a deoxyribonucleoside).</Detail>
      <Keyword>Pyrimidine nucleoside biosynthetic process</Keyword>
      <Ontology_ID>GO:0046134</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organophosphorus stimulus. Organophosphorus is a compound containing phosphorus bound to an organic molecule; several organophosphorus compounds are used as insecticides, and they are highly toxic cholinesterase inhibitors.</Detail>
      <Keyword>Response to organophosphorus</Keyword>
      <Ontology_ID>GO:0046683</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>114</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MPVAGSELPRRPLPPAAQERDAEPRPPHGELQYLGQIQHILRCGVRKDDRTGTGTLSVFGMQARYSLRDEFPLLTTKRVFWKGVLEELLWFIKGSTNAKELSSKGVKIWDANGSRDFLDSLGFSTREEGDLGPVYGFQWRHFGAEYRDMESDYSGQGVDQLQRVIDTIKTNPDDRRIIMCAWNPRDLPLMALPPCHALCQFYVVNSELSCQLYQRSGDMGLGVPFNIASYALLTYMIAHITGLKPGDFIHTLGDAHIYLNHIEPLKIQLQREPRPFPKLRILRKVEKIDDFKAEDFQIEGYNPHPTIKMEMAV</Protein_Seq>
    <DNA_Seq>GGGGGGGGGGGGACCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCCGCCCGCCGCGCCATGCCTGTGGCCGGCTCGGAGCTGCCGCGCCGGCCCTTGCCCCCCGCCGCACAGGAGCGGGACGCCGAGCCGCGTCCGCCGCACGGGGAGCTGCAGTACCTGGGGCAGATCCAACACATCCTCCGCTGCGGCGTCAGGAAGGACGACCGCACGGGCACCGGCACCCTGTCGGTATTCGGCATGCAGGCGCGCTACAGCCTGAGAGATGAATTCCCTCTGCTGACAACCAAACGTGTGTTCTGGAAGGGTGTTTTGGAGGAGTTGCTGTGGTTTATCAAGGGATCCACAAATGCTAAAGAGCTGTCTTCCAAGGGAGTGAAAATCTGGGATGCCAATGGATCCCGAGACTTTTTGGACAGCCTGGGATTCTCCACCAGAGAAGAAGGGGACTTGGGCCCAGTTTATGGCTTCCAGTGGAGGCATTTTGGGGCAGAATACAGAGATATGGAATCAGATTATTCAGGACAGGGAGTTGACCAACTGCAAAGAGTGATTGACACCATCAAAACCAACCCTGACGACAGAAGAATCATCATGTGCGCTTGGAATCCAAGAGATCTTCCTCTGATGGCGCTGCCTCCATGCCATGCCCTCTGCCAGTTCTATGTGGTGAACAGTGAGCTGTCCTGCCAGCTGTACCAGAGATCGGGAGACATGGGCCTCGGTGTGCCTTTCAACATCGCCAGCTACGCCCTGCTCACGTACATGATTGCGCACATCACGGGCCTGAAGCCAGGTGACTTTATACACACTTTGGGAGATGCACATATTTACCTGAATCACATCGAGCCACTGAAAATTCAGCTTCAGCGAGAACCCAGACCTTTCCCAAAGCTCAGGATTCTTCGAAAAGTTGAGAAAATTGATGACTTCAAAGCTGAAGACTTTCAGATTGAAGGGTACAATCCGCATCCAACTATTAAAATGGAAATGGCTGTTTAGGGTGCTTTCAAAGGAGCTTGAAGGATATTGTCAGTCTTTAGGGGTTGGGCTGGATGCCGAGGTAAAAGTTCTTTTTGCTCTAAAAGAAAAAGGAACTAGGTCAAAAATCTGTCCGTGACCTATCAGTTATTAATTTTTAAGGATGTTGCCACTGGCAAATGTAACTGTGCCAGTTCTTTCCATAATAAAAGGCTTTGAGTTAACTCACTGAGGGTATCTGACAATGCTGAGGTTATGAACAAAGTGAGGAGAATGAAATGTATGTGCTCTTAGCAAAAACATGTATGTGCATTTCAATCCCACGTACTTATAAAGAAGGTTGGTGAATTTCACAAGCTATTTTTGGAATATTTTTAGAATATTTTAAGAATTTCACAAGCTATTCCCTCAAATCTGAGGGAGCTGAGTAACACCATCGATCATGATGTAGAGTGTGGTTATGAACTTTATAGTTGTTTTATATGTTGCTATAATAAAGAAGTGTTCTGC</DNA_Seq>
  </Molecule_Seq>
  <Gene>
    <Gene_Name>TYMS</Gene_Name>
    <Gene_Alias>TS</Gene_Alias>
    <Gene_ID>7298</Gene_ID>
    <Genbank_ACCN>NM_001071</Genbank_ACCN>
    <Protein_ACCN>NP_001062</Protein_ACCN>
    <HGNC_ID>12441</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/7298</Gene_URL>
    <UCSC_ID>uc010dka.1</UCSC_ID>
    <EMBL_ID>ENSG00000176890</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Gastrointestinal Carcinoma</Disease_Name>
      <Disease_Detail>Gastrointestinal Carcinoma</Disease_Detail>
      <Disease_DB>GST071</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gastrointestinal_carcinoma?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Colorectal Cancer</Disease_Name>
      <Disease_Detail>Colorectal Cancer</Disease_Detail>
      <Disease_DB>CLR023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/colorectal_cancer?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pancreatic Cancer</Disease_Name>
      <Disease_Detail>Pancreatic Cancer</Disease_Detail>
      <Disease_DB>PNC035</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pancreatic_cancer?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemifacial Spasm</Disease_Name>
      <Disease_Detail>Hemifacial Spasm</Disease_Detail>
      <Disease_DB>HMF004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemifacial_spasm?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Adverse Reaction Due to Capecitabine Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Adverse Reaction</Disease_Detail>
      <Disease_DB>SSC044</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_adverse_reaction_due_to_capecitabine_treatment?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gastroesophageal Junction Adenocarcinoma</Disease_Name>
      <Disease_Detail>Gastroesophageal Junction Adenocarcinoma</Disease_Detail>
      <Disease_DB>GST012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gastroesophageal_junction_adenocarcinoma?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cardia Cancer</Disease_Name>
      <Disease_Detail>Cardia Cancer</Disease_Detail>
      <Disease_DB>CRD005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cardia_cancer?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Adverse Reaction Due to 5-Fluorouracil Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Adverse Reaction</Disease_Detail>
      <Disease_DB>SSC030</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_adverse_reaction_due_to_5_fluorouracil_treatment?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Lymphocytic Leukemia</Disease_Name>
      <Disease_Detail>Acute Lymphocytic Leukemia</Disease_Detail>
      <Disease_DB>ACT074</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_lymphocytic_leukemia?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Osteosarcoma</Disease_Name>
      <Disease_Detail>Osteosarcoma</Disease_Detail>
      <Disease_DB>OST018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteosarcoma?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lung Cancer</Disease_Name>
      <Disease_Detail>Lung Cancer</Disease_Detail>
      <Disease_DB>LNG032</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lung_cancer?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Benign Mesothelioma</Disease_Name>
      <Disease_Detail>Benign Mesothelioma</Disease_Detail>
      <Disease_DB>BNG032</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/benign_mesothelioma?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Colon Cancer</Disease_Name>
      <Disease_Detail>Colon Cancer</Disease_Detail>
      <Disease_DB>CLN016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/colon_cancer?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>5-Fluorouracil Toxicity</Disease_Name>
      <Disease_Detail>5-Fluorouracil Toxicity</Disease_Detail>
      <Disease_DB>5FL001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/5_fluorouracil_toxicity?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pediatric Osteosarcoma</Disease_Name>
      <Disease_Detail>Pediatric Osteosarcoma</Disease_Detail>
      <Disease_DB>PDT021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pediatric_osteosarcoma?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Capecitabine Toxicity</Disease_Name>
      <Disease_Detail>Capecitabine Toxicity</Disease_Detail>
      <Disease_DB>CPC001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/capecitabine_toxicity?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Rothmund-Thomson Syndrome</Disease_Name>
      <Disease_Detail>Rothmund-Thomson Syndrome</Disease_Detail>
      <Disease_DB>RTH001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/rothmund_thomson_syndrome?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thoracic Cancer</Disease_Name>
      <Disease_Detail>Thoracic Cancer</Disease_Detail>
      <Disease_DB>THR012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thoracic_cancer?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Adult Acute Lymphocytic Leukemia</Disease_Name>
      <Disease_Detail>Adult Acute Lymphocytic Leukemia</Disease_Detail>
      <Disease_DB>ADL052</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/adult_acute_lymphocytic_leukemia?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ovarian Cancer</Disease_Name>
      <Disease_Detail>Ovarian Cancer</Disease_Detail>
      <Disease_DB>OVR042</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ovarian_cancer?search=TYMS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gallbladder Cancer</Disease_Name>
      <Disease_Detail>Gallbladder Cancer</Disease_Detail>
      <Disease_DB>GLL018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gallbladder_cancer?search=TYMS#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability</PDB_Title>
      <PDB_ID>3EBU</PDB_ID>
      <Resolution>2.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EBU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1,2-ETHANEDIOL</Ligand_Name>
      <PubMed_Title>Replacement of Val3 in human thymidylate synthase affects its kinetic properties and intracellular stability .</PubMed_Title>
      <Author>Huang X, et al.</Author>
      <Journal>Biochemistry. 2010 Mar 23;49(11):2475-82</Journal>
      <PubMed_ID>20151707</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability</PDB_Title>
      <PDB_ID>3GH2</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GH2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Replacement of Val3 in human thymidylate synthase affects its kinetic properties and intracellular stability .</PubMed_Title>
      <Author>Huang X, et al.</Author>
      <Journal>Biochemistry. 2010 Mar 23;49(11):2475-82</Journal>
      <PubMed_ID>20151707</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF HUMAN THYMIDYLATE SYNTHASE SUGGESTS ADVANTAGES OF CHEMOTHERAPY WITH NONCOMPETITIVE INHIBITORS</PDB_Title>
      <PDB_ID>1HW3</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HW3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1,2-ETHANEDIOL</Ligand_Name>
      <PubMed_Title>Structure of human thymidylate synthase suggests advantages of chemotherapy with noncompetitive inhibitors</PubMed_Title>
      <Author>Phan J, et al.</Author>
      <Journal>J Biol Chem. 2001 Apr 27;276(17):14170-7. Epub 2001 Jan 24</Journal>
      <PubMed_ID>11278511</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF THYMIDYLATE SYNTHASE SUGGESTS ADVANTAGES OF CHEMOTHERAPY WITH NONCOMPETITIVE INHIBITORS</PDB_Title>
      <PDB_ID>1HW4</PDB_ID>
      <Resolution>2.06</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HW4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1,2-ETHANEDIOL</Ligand_Name>
      <PubMed_Title>Structure of human thymidylate synthase suggests advantages of chemotherapy with noncompetitive inhibitors</PubMed_Title>
      <Author>Phan J, et al.</Author>
      <Journal>J Biol Chem. 2001 Apr 27;276(17):14170-7. Epub 2001 Jan 24</Journal>
      <PubMed_ID>11278511</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Allosteric peptidic inhibitor of human thymidylate synthase that stabilizes inactive conformation of the enzyme.</PDB_Title>
      <PDB_ID>4FGT</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4FGT</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02810013</ASD_Ligand>
      <PubMed_Title>Alanine mutants of the interface residues of human thymidylate synthase decode key features of the binding mode of allosteric anticancer peptides.</PubMed_Title>
      <Author>Tochowicz, A., et al.</Author>
      <Journal>J.Med.Chem.(2015)58:1012-1018</Journal>
      <PubMed_ID>25427005</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability</PDB_Title>
      <PDB_ID>3EDW</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EDW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Replacement of Val3 in human thymidylate synthase affects its kinetic properties and intracellular stability .</PubMed_Title>
      <Author>Huang X, et al.</Author>
      <Journal>Biochemistry. 2010 Mar 23;49(11):2475-82</Journal>
      <PubMed_ID>20151707</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Thymidylate Synthase Stabilized in Active Conformation by R163K Mutation: Asymmetry and Reactivity of Cys195</PDB_Title>
      <PDB_ID>2RDA</PDB_ID>
      <Resolution>2.67</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2RDA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>BETA-MERCAPTOETHANOL</Ligand_Name>
      <PubMed_Title>The R163K mutant of human thymidylate synthase is stabilized in an active conformation: structural asymmetry and reactivity of cysteine 195.</PubMed_Title>
      <Author>Gibson LM, et al.</Author>
      <Journal>Biochemistry. 2008 Apr 22;47(16):4636-43. Epub 2008 Mar 28.</Journal>
      <PubMed_ID>18370400</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN THYMIDYLATE SYNTHASE, TERNARY COMPLEX WITH DUMP AND TOMUDEX</PDB_Title>
      <PDB_ID>1I00</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1I00</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>TOMUDEX$2'-DEOXYURIDINE 5'-MONOPHOSPHATE</Ligand_Name>
      <PubMed_Title>Crystal structure of a deletion mutant of human thymidylate synthase Delta (7-29) and its ternary complex with Tomudex and dUMP.</PubMed_Title>
      <Author>Almog R, et al.</Author>
      <Journal>Protein Sci. 2001 May;10(5):988-96.</Journal>
      <PubMed_ID>11316879</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Thymidylate Synthase Bound to dUMP and LY231514, a Pyrrolo(2,3-d)pyrimidine-based Antifolate</PDB_Title>
      <PDB_ID>1JUJ</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1JUJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3- D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID$2'-DEOXYURIDINE 5'-MONOPHOSPHATE</Ligand_Name>
      <PubMed_Title>Multi-targeted antifolates aimed at avoiding drug resistance form covalent closed inhibitory complexes with human and Escherichia coli thymidylate synthases</PubMed_Title>
      <Author>Sayre PH, et al.</Author>
      <Journal>J Mol Biol. 2001 Nov 2;313(4):813-29</Journal>
      <PubMed_ID>11697906</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability</PDB_Title>
      <PDB_ID>3EJL</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EJL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-FLUORO-2'-DEOXYURIDINE-5'-MONOPHOSPHATE</Ligand_Name>
      <PubMed_Title>Replacement of Val3 in human thymidylate synthase affects its kinetic properties and intracellular stability .</PubMed_Title>
      <Author>Huang X, et al.</Author>
      <Journal>Biochemistry. 2010 Mar 23;49(11):2475-82</Journal>
      <PubMed_ID>20151707</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human thymidylate synthase complexed with dUMP and Raltitrexed, an antifolate drug, is in the closed conformation</PDB_Title>
      <PDB_ID>1HVY</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HVY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>BETA-MERCAPTOETHANOL$TOMUDEX$2'-DEOXYURIDINE 5'-MONOPHOSPHATE</Ligand_Name>
      <PubMed_Title>Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antifolate drug.</PubMed_Title>
      <Author>Phan J, et al.</Author>
      <Journal>Biochemistry. 2001 Feb 20;40(7):1897-902.</Journal>
      <PubMed_ID>11329255</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structures of Thymidylate Synthase R163K with Substrates and Inhibitors Show Subunit Asymmetry</PDB_Title>
      <PDB_ID>3H9K</PDB_ID>
      <Resolution>2.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3H9K</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1,2-ETHANEDIOL$PHOSPHATE ION$5-FLUORO-2'-DEOXYURIDINE-5'-MONOPHOSPHATE</Ligand_Name>
      <PubMed_Title>Structures of Thymidylate Synthase R163K with Substrates and Inhibitors Show Subunit Asymmetry</PubMed_Title>
      <Author>Gibson LM, et al.</Author>
      <Journal>to be published</Journal>
    </PDB>
    <PDB>
      <PDB_Title>Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability</PDB_Title>
      <PDB_ID>3EF9</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EF9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Replacement of Val3 in human thymidylate synthase affects its kinetic properties and intracellular stability .</PubMed_Title>
      <Author>Huang X, et al.</Author>
      <Journal>Biochemistry. 2010 Mar 23;49(11):2475-82</Journal>
      <PubMed_ID>20151707</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Human Thymidyalte Synthase A191K with Loop 181-197 stabilized in the inactive conformation</PDB_Title>
      <PDB_ID>3EGY</PDB_ID>
      <Resolution>2.18</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EGY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1,2-ETHANEDIOL</Ligand_Name>
      <PubMed_Title>Variants of human thymidylate synthase with loop 181-197 stabilized in the inactive conformation.</PubMed_Title>
      <Author>Lovelace LL, et al.</Author>
      <Journal>Protein Sci. 2009 Aug;18(8):1628-36.</Journal>
      <PubMed_ID>19569192</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Thymidylate Synthase Stabilized in Active Conformation by R163K Mutation: Asymmetry and Reactivity of Cys195</PDB_Title>
      <PDB_ID>2RD8</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2RD8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>BETA-MERCAPTOETHANOL</Ligand_Name>
      <PubMed_Title>The R163K mutant of human thymidylate synthase is stabilized in an active conformation: structural asymmetry and reactivity of cysteine 195.</PubMed_Title>
      <Author>Gibson LM, et al.</Author>
      <Journal>Biochemistry. 2008 Apr 22;47(16):4636-43. Epub 2008 Mar 28.</Journal>
      <PubMed_ID>18370400</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Human Thymidyalte Synthase M190K with Loop 181-197 stabilized in the inactive conformation</PDB_Title>
      <PDB_ID>3EHI</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EHI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1,2-ETHANEDIOL</Ligand_Name>
      <PubMed_Title>Variants of human thymidylate synthase with loop 181-197 stabilized in the inactive conformation.</PubMed_Title>
      <Author>Lovelace LL, et al.</Author>
      <Journal>Protein Sci. 2009 Aug;18(8):1628-36.</Journal>
      <PubMed_ID>19569192</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability</PDB_Title>
      <PDB_ID>3ED7</PDB_ID>
      <Resolution>1.56</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ED7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Replacement of Val3 in human thymidylate synthase affects its kinetic properties and intracellular stability .</PubMed_Title>
      <Author>Huang X, et al.</Author>
      <Journal>Biochemistry. 2010 Mar 23;49(11):2475-82</Journal>
      <PubMed_ID>20151707</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of a deletion mutant of human thymidylate synthase Delta (7-29) and its ternary complex with Tomudex and dUMP</PDB_Title>
      <PDB_ID>1HZW</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HZW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of a deletion mutant of human thymidylate synthase Delta (7-29) and its ternary complex with Tomudex and dUMP.</PubMed_Title>
      <Author>Almog R, et al.</Author>
      <Journal>Protein Sci. 2001 May;10(5):988-96.</Journal>
      <PubMed_ID>11316879</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability</PDB_Title>
      <PDB_ID>3EAW</PDB_ID>
      <Resolution>1.86</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EAW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1,2-ETHANEDIOL</Ligand_Name>
      <PubMed_Title>Replacement of Val3 in human thymidylate synthase affects its kinetic properties and intracellular stability .</PubMed_Title>
      <Author>Huang X, et al.</Author>
      <Journal>Biochemistry. 2010 Mar 23;49(11):2475-82</Journal>
      <PubMed_ID>20151707</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human thymidylate synthase at low salt conditions</PDB_Title>
      <PDB_ID>1YPV</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YPV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of human thymidylate synthase under low-salt conditions</PubMed_Title>
      <Author>Lovelace LL, et al.</Author>
      <Journal>Acta Crystallogr D Biol Crystallogr. 2005 May;61(Pt 5):622-7. Epub 2005 Apr 20.</Journal>
      <PubMed_ID>15858273</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Thymidylate Synthase at low salt conditions with PDPA bound</PDB_Title>
      <PDB_ID>2ONB</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ONB</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02810004</ASD_Ligand>
      <Ligand_Name>PROPANE-1,3-DIYLBIS(PHOSPHONIC ACID)$1,2-ETHANEDIOL</Ligand_Name>
      <PubMed_Title>Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors</PubMed_Title>
      <Author>Lovelace LL, et al.</Author>
      <Journal>Biochemistry. 2007 Mar 13;46(10):2823-30. Epub 2007 Feb 13.</Journal>
      <PubMed_ID>17297914</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Thymidylate Synthase Complex with dUMP and LY231514, A Pyrrolo(2,3-d)pyrimidine-based Antifolate</PDB_Title>
      <PDB_ID>1JU6</PDB_ID>
      <Resolution>2.89</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1JU6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3- D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID$2'-DEOXYURIDINE 5'-MONOPHOSPHATE</Ligand_Name>
      <PubMed_Title>Multi-targeted antifolates aimed at avoiding drug resistance form covalent closed inhibitory complexes with human and Escherichia coli thymidylate synthases</PubMed_Title>
      <Author>Sayre PH, et al.</Author>
      <Journal>J Mol Biol. 2001 Nov 2;313(4):813-29</Journal>
      <PubMed_ID>11697906</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability</PDB_Title>
      <PDB_ID>3GH0</PDB_ID>
      <Resolution>1.56</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GH0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Replacement of Val3 in human thymidylate synthase affects its kinetic properties and intracellular stability .</PubMed_Title>
      <Author>Huang X, et al.</Author>
      <Journal>Biochemistry. 2010 Mar 23;49(11):2475-82</Journal>
      <PubMed_ID>20151707</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Replacement of Val3 in Human Thymidylate Synthase Affects Its Kinetic Properties and Intracellular Stability</PDB_Title>
      <PDB_ID>3GG5</PDB_ID>
      <Resolution>2.77</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GG5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Replacement of Val3 in human thymidylate synthase affects its kinetic properties and intracellular stability .</PubMed_Title>
      <Author>Huang X, et al.</Author>
      <Journal>Biochemistry. 2010 Mar 23;49(11):2475-82</Journal>
      <PubMed_ID>20151707</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko00670</Pathway_ID>
      <Pathway_Title>One carbon pool by folate</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Metabolism of cofactors and vitamins</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00240</Pathway_ID>
      <Pathway_Title>Pyrimidine metabolism</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Nucleotide metabolism</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.e.cei.b.b.h.html</SCOP_URL>
    <CATH_Class>Mixed alpha-beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1hw4</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Detail>site,183,Asn;site,175,Arg;site,258,Tyr</Site_Detail>
      <Site_Reference>Lovelace LL, et al. Biochemistry. 2007,46(10):2823-2830.</Site_Reference>
      <Site_Type>Nested subunit-subunit interactions</Site_Type>
      <PDB_ID>2ONB</PDB_ID>
      <PubMed_ID>17297914</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.1.1.45</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/1/1/45.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD02810001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02810002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02810003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02810004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02810005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02810006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02810007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02810008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02810009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02810010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02810011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02810012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02810013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05892001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>